Pharma Horizons: Biologics
Supported by:
Published: 25 September 2024
Share this post
2
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
European Pharmaceutical Review’s latest Pharma Horizons report provides insight on key developments in pharmaceutical biologics for drug development, pharmaceutical manufacturing and quality control.
This report delves into the latest developments impacting the pharmaceutical biologic drug sector today. Inside, articles explore current key topics including biosimilars, antibody drugs, manufacturing, drug delivery and vaccines.
Stay up to date with the latest developments in biologics including articles on:
- Navigating the demanding biosimilar landscape and improving patient access to biologic therapies
- Preventing infectious diseases with innovative vaccine development
- Current trends and future outlook for achieving optimal quality control in antibody drug conjugate (ADC) drug development
- The major challenges and solutions in continuous manufacturing of biologic therapeutics, highlighting quality control considerations
- The potential of subcutaneous injectable drugs as a solution to overcome a key obstacle in biologic drug delivery.
Register now to access this exclusive content as we discover some of the challenges and opportunities for biologic drugs in pharma, with exclusive insight from:
- Peter Stenico, Biosimilar Global Head and Country President Austria at Sandoz
- Dr Hanneke Schuitemaker, Chief Scientific Officer of Valneva
- Rashida Najmi, Chief Quality Officer, Piramal Pharma Limited
- Dr Sundar Ramanan, Chief Quality Officer, Enzene Biosciences
- Deborah Bitterfield, CEO of Lindy Biosciences.
